Investors reality check

Markets, policy & media — without the noise. Fact-driven takes on stocks, narratives & economic shifts. #Investing #Macro #RealityCheck

[Investors reality check @Investor1Fact]

@karlovric @Aktieland @grok @grok

[Investors reality check @Investor1Fact]

@karlovric @Aktieland @grok @grok, but if only looked at the result and not the stock right now - should it raise or fall?

[Investors reality check @Investor1Fact]

Novo is being priced like the growth story is over.

Meanwhile, investors get a 3.5% yield, a payout ratio around 40% and exposure to one of the biggest healthcare markets of the next decade.

The market sees a broken story. I see a reset with serious upside. $NVO

https://t.co/mmwNB39CJz

[Investors reality check @Investor1Fact]

@jimcramer Jim, “fired up” over a President mocking the Chief Justice? That isn’t analysis. It’s cheerleading for the erosion of checks and balances.

[Investors reality check @Investor1Fact]

Novo is done playing defense.

Taking Lilly to court puts the spotlight on what really matters: fair dose comparisons, current clinical evidence, and the true competitive strength of Wegovy.

This could become an important battle for market perception in obesity care. $NVO

[Investors reality check @Investor1Fact]

AstraZeneca’s setback is another reminder that pharma is all about execution and pipeline quality. That’s also why companies like Novo Nordisk continue to stand out—the market rewards businesses with strong science, consistent execution and confidence in future innovation. One failed trial doesn’t define AstraZeneca, but it certainly raises the bar.

[Novo Nordisk @novonordisk]

Novo Nordisk and @OpenAI partner to transform how medicines are discovered and delivered. Read more here:
https://t.co/JJoSqHmOzA

[Investors reality check @Investor1Fact]

@grok @WhiteHouse @grok Trump has stated that tariffs will still happen “as agreed,” just implemented differently using Section 232 and 301. Is that actually accurate?

[Investors reality check @Investor1Fact]

@grok @JerBearRN @wearehims @wearehers @grok no not HIMS. That pill showed on the photo - is it Novo nordisk new oral pill? Novo have a partnership with Amazon

[Investors reality check @Investor1Fact]

@grok @TheStockerMan @grok Guidance wasn’t raised. Labs hasn’t contributed. Multiple assumes success already. Core telehealth growth is slowing, CAC is rising, and competition is intensifying
If Labs doesn’t materially accelerate revenue and margins, the current valuation isn’t cheap - it’s exposed.

[Investors reality check @Investor1Fact]

@grok @TheStockerMan @grok Q3 growth was driven by legacy telehealth — not Labs.

At ~$3.6B market cap, investors are already paying for execution that hasn’t shown up in financials.

If Labs is the upside — why hasn’t guidance materially changed yet?

[Investors reality check @Investor1Fact]

@grok @TheStockerMan @grok If closed-loop care is the advantage — where is the earnings impact?

$HIMS launched Labs in Nov 2025, yet no material revenue contribution so far.

So what exactly justifies premium multiples today — execution, or just narrative?

[Investors reality check @Investor1Fact]

@wave3trades @MMatters22596 $HIMS to $70? Not a chance.
Their GLP-1 growth depends on compounded copies that disappear if courts side with Novo Nordisk. No moat, 54x P/E, legal risk everywhere. That’s not upside — that’s bankruptcy risk. $NVO wins.

[Investors reality check @Investor1Fact]

Pharma “copycats” calling patents anti-consumer is wild.

Novo spent billions on R&D, clinical trials, and FDA approvals to prove safety & efficacy.
Others compound versions during shortages and call it “access.”

Innovation has costs. Free-riding isn’t disruption.

$NVO $HIMS

[Investors reality check @Investor1Fact]

@HimsHersComms Calling this “choice” is misleading. Compounded GLP-1 copies skip FDA trials and Novo’s IP while monetizing their R&D. That’s not healthcare innovation — it’s regulatory arbitrage dressed up as access.

[Investors reality check @Investor1Fact]

@grok @himshouse @grok If GLP-1s drove ~$725M and they’ve halted the product with no FDA approval, what’s left to justify a 54x P/E? Isn’t $HIMS just a low-margin telehealth play without Novo’s IP tailwind—and shouldn’t fair value reset much lower?